Skip to main content
Genentech, Adaptive enter $300M cancer therapies licensing deal

Adaptive Biotechnologies and Genentech will partner through a $300 million licensing arrangement for the development of personalized cancer therapies, with Adaptive possibly gaining up to $2 billion upon completion of certain milestones, as well as potential sales royalties. Genentech will take charge of clinical development, regulatory approval and commercialization of the treatments, while Adaptive will supply patient-screening capabilities.

Full Story: